Ipsen’s Iqirvo accepted by SMC to treat rare liver disease primary biliary cholangitis - PMLiVE The life-long condition affects approximately 1,900 people in Scotland

#hepatology #gastroenterology #Ipsen #Iqirvo #elafibranor #SMC #ScottishMedicinesConsortium #SMCapprovel #liverdisease #primarybiliarycholangitis #Scotland #NHSScotland #rarecholestaticliverdisease #NICE #NICErecommended #PBCpatients #ELATIVEtrial #cholestasis
pmlive.com/ipsens-iqirv...

#IQIRVO @IpsenUS is indicated for the treatment of primary biliary cholangitis #PBC in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
#livertwitter

drug-drug interactions for #elafibranor #iqirvo @IpsenUS
-non hormonal contraception: barrier contraceptive/IUD
-watch liver function tests if need to give rifampin
give at least 4 hours away from cholestyramine or cholestipol

some highlights of the #iqirvo label:
80 mg w/wo food
only limitation of use is decomp cirrhosis
evaluate for muscle pain or myopathy before initiation
verify effective contraception and pregnancy status in women in reproductive age group
#livertwitter

It's a good day for persons living with #PBC with the approval of #elafibranor #iqirvo 80 mg @PBCers @pbcercarol @UKPBC_Project

#livertwitter